Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The case for hepatitis C arthritis.

Itzhak Rosner1, Michael Rozenbaum, Elias Toubi

  • 1Department of Rheumatology, Bnai Zion Medical Center, Faculty of Medicine, Technion, Haifa, Israel. rosneri@tx.technion.ac.il

Seminars in Arthritis and Rheumatism
|June 11, 2004
PubMed
Summary

Hepatitis C virus (HCV) infection can cause a rheumatoid-like arthritis in 2% to 20% of patients. This viral arthropathy requires consideration in new-onset arthritis diagnoses.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-World Variation in Post-Dose Supervision and Activity Restriction During Maintenance Cow's Milk Oral Immunotherapy.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Sebetralstat for on-demand treatment of hereditary angioedema: A pooled analysis of placebo-controlled clinical trials.

The World Allergy Organization journal·2026
Same author

[Primary Prevention of Food Allergies - Is It Feasible?]

Harefuah·2026
Same author

The 2025 WAO Guidelines for the classification, diagnosis, and treatment of hereditary angioedema, with consideration of worldwide disparities.

The World Allergy Organization journal·2026
Same author

Adherence and sustained virologic response in HCV treatment: A real-world comparison of major pangenotypic direct-acting antivirals.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research·2026
Same author

Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trial.

The Lancet. Haematology·2026

Area of Science:

  • Rheumatology
  • Hepatology
  • Infectious Diseases

Background:

  • Hepatitis C virus (HCV) infection is a significant global health concern.
  • A subset of HCV patients develop joint complications, termed HCV arthropathy.
  • The exact pathogenesis and clinical spectrum of HCV arthropathy are not fully elucidated.

Purpose of the Study:

  • To consolidate and present existing data on arthropathy associated with hepatitis C infection.
  • To highlight the clinical characteristics and diagnostic considerations of HCV-related arthritis.
  • To discuss therapeutic approaches for managing arthropathy in HCV patients.

Main Methods:

  • Systematic literature search of MEDLINE database using keywords 'arthritis' and 'hepatitis C'.
  • Inclusion of authors' personal investigations and clinical experience.

Related Experiment Videos

  • Review of reported cases and epidemiological data on HCV arthropathy.

    • Main Results:

    • Arthritis affects 2% to 20% of hepatitis C virus (HCV) patients.
    • The arthritis is typically rheumatoid-like (two-thirds of cases) or a waxing/waning oligoarthritis.
    • HCV arthropathy is nonerosive/nondeforming, and cryoglobulinemia does not fully explain it.
    • Conventional arthritis treatments may be challenging; antiviral therapy is most effective.
    • Rheumatic complications can occur even with successful antiviral treatment.

    Conclusions:

    • HCV arthropathy is a distinct clinical entity that warrants consideration in the differential diagnosis of new-onset arthritis.
    • Early recognition and appropriate management, potentially including antiviral therapy, are crucial for patients with HCV-associated joint disease.